134 related articles for article (PubMed ID: 38044812)
21. Retrospective analysis of management of patients presenting with acute urinary retention due to benign prostatic hyperplasia: a hospital based study.
Pandit RK; Agrawal CS; Chalise PR; Sapkota G
Kathmandu Univ Med J (KUMJ); 2008; 6(24):448-52. PubMed ID: 19483424
[TBL] [Abstract][Full Text] [Related]
22. [Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect].
Lorente Garín JA; Cañis Sánchez D; Arango Toro O; Bielsa Gali O; Cortadellas Angel R; Gelabert Mas A
Actas Urol Esp; 2004 Jan; 28(1):32-7. PubMed ID: 15046478
[TBL] [Abstract][Full Text] [Related]
23. Does sildenafil enhance the effect of tamsulosin in relieving acute urinary retention?
Sharifi SH; Mokarrar MH; Khaledi F; Yamini-Sharif R; Lashay A; Soltani MH
Int Braz J Urol; 2014; 40(3):373-8. PubMed ID: 25010303
[TBL] [Abstract][Full Text] [Related]
24. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
McNeill SA; Hargreave TB;
J Urol; 2004 Jun; 171(6 Pt 1):2316-20. PubMed ID: 15126812
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia.
Lo KL; Chan MC; Wong A; Hou SM; Ng CF
Int Urol Nephrol; 2010 Mar; 42(1):7-12. PubMed ID: 19449121
[TBL] [Abstract][Full Text] [Related]
26. Factors predicting the success of a trial without catheter in acute urinary retention secondary to benign prostatic hyperplasia.
Bhomi KK; Bhattachan CL
Nepal Med Coll J; 2011 Sep; 13(3):178-81. PubMed ID: 22808810
[TBL] [Abstract][Full Text] [Related]
27. [Alpha-adrenergic blockers as a support in the treatment of acute urinary retention].
Altarac S
Lijec Vjesn; 2006; 128(7-8):233-7. PubMed ID: 17087140
[TBL] [Abstract][Full Text] [Related]
28. Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey.
Manikandan R; Srirangam SJ; O'Reilly PH; Collins GN
BJU Int; 2004 Jan; 93(1):84-8. PubMed ID: 14678374
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia.
Prieto L; Romero J; López C; Ortiz M; Pacheco JJ
Urol Int; 2008; 81(1):66-71. PubMed ID: 18645274
[TBL] [Abstract][Full Text] [Related]
30. The effect of acute urinary retention on the results of transurethral resection of the prostate.
Baran C
Urologia; 2023 Nov; 90(4):642-646. PubMed ID: 37491943
[TBL] [Abstract][Full Text] [Related]
31. The effect of sublingual isosorbide dinitrate on acute urinary retention due to benign prostatic hyperplasia.
Tadayyon F; Izadpanahi M; Aali S; Mazdak H; Khorrami MH
Saudi J Kidney Dis Transpl; 2012 Jul; 23(4):782-5. PubMed ID: 22805391
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of in-and-out catheterization as a way of trial without catheterization strategy for treatment of acute urinary retention induced by benign prostate hyperplasia: variables predicting success outcome.
Ko YH; Kim JW; Kang SG; Jang HA; Kang SH; Park HS; Moon du G; Cheon J; Kim JJ; Lee JG
Neurourol Urodyn; 2012 Apr; 31(4):460-4. PubMed ID: 22331691
[TBL] [Abstract][Full Text] [Related]
33. Predicting the risk of failed trial without catheter following Rezum™ therapy.
Coscarella M; Al Barajraji M; Moussa I; Hombert L; Naudin M; Roumeguère T
World J Urol; 2024 Mar; 42(1):129. PubMed ID: 38460028
[TBL] [Abstract][Full Text] [Related]
34. Does acute urinary retention respond to alpha-blockers alone?
McNeill SA
Eur Urol; 2001 Mar; 39 Suppl 6():7-12. PubMed ID: 11306895
[TBL] [Abstract][Full Text] [Related]
35. Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
AbdelRazek M; Abolyosr A; Mhammed O; Fathi A; Talaat M; Hassan A
World J Urol; 2022 Aug; 40(8):2063-2070. PubMed ID: 35773357
[TBL] [Abstract][Full Text] [Related]
36. Prostate size influences the outcome after presenting with acute urinary retention.
McNeill AS; Rizvi S; Byrne DJ
BJU Int; 2004 Sep; 94(4):559-62. PubMed ID: 15329112
[TBL] [Abstract][Full Text] [Related]
37. A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol.
Gopi SS; Goodman CM; Robertson A; Byrne DJ
ScientificWorldJournal; 2006 Jun; 6():2436-41. PubMed ID: 17619714
[TBL] [Abstract][Full Text] [Related]
38. Α₁-blockers in the management of acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Guang-Jun D; Feng-Bin G; Xun-Bo J
Ir J Med Sci; 2015 Mar; 184(1):23-30. PubMed ID: 24599498
[TBL] [Abstract][Full Text] [Related]
39. Predictive factors for the success of trial without catheter for men with urinary retention.
Takanashi M; Ito H; Fukazawa T; Takizawa H; Hioki M; Shinoki R; Kawahara T; Kobayashi K
Low Urin Tract Symptoms; 2023 Sep; 15(5):173-179. PubMed ID: 37278133
[TBL] [Abstract][Full Text] [Related]
40. Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis.
Gwon YN; Park JJ; Yang WJ; Doo SW; Kim JH; Kim DK
Prostate Int; 2023 Jun; 11(2):91-99. PubMed ID: 37409094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
